Vivek Subbiah: This recognition is incredibly humbling and I am beyond grateful

Vivek Subbiah, recently posted on LinkedIn:

“This recognition is incredibly humbling and I am beyond grateful.

My heartfelt thanks to my patients, collaborators in academia/industry/FDA/community, mentors/sponsors, my extraordinary colleagues, and everyone. This award is a testament to our collective efforts. Much love and appreciation!

This award belongs to all of you!”

Vivek Subbiah Receives 2024 Yvonne Award in the Voice of Oncology Category

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.